Anthony E. Maida III
CIK: 0001273213
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
OTLC
Oncotelic Therapeutics, Inc.
DirectorOfficer
Discretionary Trading P&L
Holdings
About MAIDA ANTHONY E III
MAIDA ANTHONY E III (SEC CIK 0001273213) files insider reports with the SEC as DIRECTOR AND CMO - TRANS. MED. of Oncotelic Therapeutics, Inc. (OTLC).
Signal8 holds 1 ownership filing by MAIDA ANTHONY E III, a Form 4, filed on Jul 14, 2026. Those filings report 1 transaction, the latest on Jul 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on MAIDA ANTHONY E III's filings is in AGOURA HILLS, CA.
Recent filings by MAIDA ANTHONY E III
- Jul 10, 2026: Grant or award of OTLC derivative securities (Form 4, code A).
Other insiders filing for Oncotelic Therapeutics, Inc. (OTLC)
- Trieu Vuong, CHAIRMAN AND CEO
- Fein Seymour Howard, CRO/CMO
- KING STEVEN W, Director
- Saund Saran, CBO
- Shah Amit B., CFO